SIGN guideline: Cardiovascular Heart Disease, Subgroup Heart Failure Published: 11 March 2016

	Financial		Non-financial		Non- personal	Date received at SIGN Executive	Action
	Specific	Non-Specific	Specific	Non-Specific			
CHAIR							
Allan Struthers, Head of Cardiovascular & Diabetes Medicine	Professor of Cardiovascular Medicine – University of Dundee. One talk – Marck, Serono One talk (on non heart failure topic) – Astra Zeneca One talk – Ceva Sante Animale (specific to vet medicine). Chairman of the Data & Safety monitoring committee (DSMC) – 28.1.16.	Research grant for research in non heart failure topic to my research team – Astra Zeneca (money to university not me). Patent on use of xanthine oxidase inhibitors in angina (Self and university)	None	None	Boehringer - £1500 Roche - £750 Takeda - £500 Pfizer - £750 Abbott - £750 Servier - £750 Alere - £750 Bayer - £1000 As President of the Scottish Society of Physicians (SSP) for 2014, I raised money for the SSP meeting from several companies. All money for meeting costs only.	14.7.15	Declare and participate

SIGN guideline: Cardiovascular Heart Disease, Subgroup Heart Failure Published: 11 March 2016

Lynda Blue, BHF Regional	Healthcare and	None	None	None	None	17.7.15	No action
Service Development Manager	Innovation Programme Manager (British Heart Foundation)						required
Anna Maria Choy, Consultant Cardiologist	Cardiologist working for NHS Tayside and Senior Lecturer at University of Dundee.	Unrestricted educational grants for sponsorship for the Familial Arrhythmia network of Scotland. Travel sponsorship from Biotronik, Boston Scientific, Medtronic, Daichi, Sankyo. Unrestricted research funding from St Jude medical.	None	None	None	22.2.16	Declare and participate
Jane Church, General Practitioner	General Pracitioner, Blackfriars Medical Practice, St Andrews. Partner in this practice.	None	None	None	None	8.10.15	No action required
Martin Denvir, Consultant Cardiologist	Medical practitioner/cardiologist – NHS	Trial endnote committee – GSK.	None	None	None	7.3.16	Declare and participate

SIGN guideline: Cardiovascular Heart Disease, Subgroup Heart Failure Published: 11 March 2016

	Lothian/University of Edinburgh.	Lecture fees – Pfizer.					
Sarah Fraser, Lay Representative	None	None	None	None	None	10.11.15	No action required
Kenneth Halliday, Locality Clinical Pharmacist	Locality Pharmacist, NHS Tayside.	None	None	None	None	20.7.15	No action required
Karen Hogg, Consultant Cardiologist (Palliative Care)	Consultant Cardiologist, Glasgow Royal Infirmary, Glasgow, NHS GGC.	None	None	Caring Together Clinical Lead (BHF, MCCC, GGC, GCU). Clinical lead for the National Heart Failure and Palliative Care programme.	None	7.3.16	Declare and participate
Pardeep Jhund, Clinical Lecturer in Cardiology	Senior Clinical Lecturer in Cardiology and Honorary Consultant Cardiologist (University of Glasgow)	None	None	I have acted as a non-paid consultant to Novartis. I was a member of the endpoint committee for PARADIGM-	None	14.7.15	Escalated to SMT Declare and participate

SIGN guideline: Cardiovascular Heart Disease, Subgroup Heart Failure Published: 11 March 2016

				HF			
Jill Nicholls, Heart Failure Specialist Nurse	Heart Failure Specialist Nurse, NHS Tayside.	None	None	Funded trip to HF Summit, Barcelona Oct 2015. Novartis (one off)	None	7.10.15	Declare and participate
John Sharp, Consultant Clinical Psychologist	Consultant Clinical Psychologist (NHS NWTC)	None	None	None	None	14.7.15	No action required
Amanda Smith, Lead Heart Failure Nurse	Lead Heart Failure Nurse, Raigmore Hospital, Inverness.	None	None	None	None	7.3.16	No action required